Published online Aug 26, 2020. doi: 10.12998/wjcc.v8.i16.3458
Peer-review started: April 9, 2020
First decision: April 29, 2020
Revised: May 12, 2020
Accepted: July 14, 2020
Article in press: July 14, 2020
Published online: August 26, 2020
Processing time: 137 Days and 23.8 Hours
The incidence and prevalence of atrial fibrillation are increasing each year, and this condition is one of the most common clinical arrhythmias
The identification of useful serological markers can provide guidance for the primary prevention of atrial fibrillation and for monitoring and evaluating treatment efficacy and prognosis
To investigate the levels and significance of serum fibroblast growth factor (FGF)-23 and miR-208b in atrial fibrillation and their relevance to patient prognosis
A total of 240 patients with atrial fibrillation treated at our hospital from May 2018 to October 2019 were included.
The serum levels of FGF-23 and miR-208b in the observation group were significantly higher than the corresponding values in the control group. In the observation group, the serum levels of FGF-23 and miR-208b in patients with persistent atrial fibrillation were significantly higher than those in patients with paroxysmal atrial fibrillation. The left atrial dimension (LAD) of patients with persistent atrial fibrillation was significantly higher than that of patients with paroxysmal atrial fibrillation. The serum levels of FGF-23 and miR-208b were positively correlated with the LAD. In the observation group, the serum levels of FGF-23 and miR-208b in patients with a major cardiovascular event (MACE) were significantly higher than the corresponding values in patients without a MACE.
Serum FGF-23 and miR-208b levels are elevated in patients with atrial fibrillation and correlate with disease type, cardiac parameters, and prognosis.
Our findings may suggest a new method for evaluating the condition of atrial fibrillation.